Related Experiment Video
Updated: Jun 23, 2026

10:28
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
Aberrant ENaC activation in Dahl salt-sensitive rats
Yutaka Kakizoe1, Kenichiro Kitamura, Takehiro Ko
1Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto 860-8556, Japan.
Journal of Hypertension
|May 22, 2009
Summary
High-salt diets activate the epithelial sodium channel (ENaC) in Dahl salt-sensitive rats, leading to hypertension and kidney damage. Amiloride treatment effectively reduced these effects, suggesting ENaC
Area of Science:
- Nephrology
- Cardiovascular Physiology
- Molecular Biology
Background:
- The epithelial sodium channel (ENaC) is crucial for regulating blood pressure via kidney sodium reabsorption.
- Dahl salt-sensitive rats exhibit hypertension on high-salt diets, with abnormal ENaC mRNA expression despite low aldosterone.
Purpose of the Study:
- To investigate the impact of high-salt diet on ENaC protein expression in rat models.
- To evaluate the therapeutic effects of amiloride and eplerenone on hypertension and kidney injury in Dahl salt-sensitive rats.
Main Methods:
- Comparative analysis of ENaC protein expression in Dahl salt-resistant and salt-sensitive rats under high-salt conditions.
- Treatment of Dahl salt-sensitive rats with amiloride or eplerenone during high-salt diet exposure.
- Assessment of blood pressure and renal damage markers.
Main Results:
- High-salt diet induced hypertension and renal damage in Dahl salt-sensitive rats.
- Despite suppressed aldosterone, beta and gammaENaC mRNA and protein levels increased, with enhanced gammaENaC activation.
- Amiloride, but not eplerenone, significantly improved blood pressure and reduced kidney injury, indicating aldosterone-independent ENaC activation.
Conclusions:
- Inappropriate ENaC expression and activation contribute to salt-sensitive hypertension and organ damage in Dahl rats.
- Amiloride shows therapeutic potential for salt-sensitive hypertension characterized by excessive ENaC activity.
